Astrazeneca (AZN) Receivables - Net (2009 - 2026)

Astrazeneca's Receivables - Net history runs 18 years deep, the most recent figure standing at $14.1 billion for Q1 2026.

• In Q1 2026, Receivables - Net rose 6.46% year-over-year to $14.1 billion; the TTM figure through Mar 2026 stood at $14.1 billion (up 6.46% YoY), while the FY2025 annual figure was $15.2 billion, up 17.0% from the prior year.
• Receivables - Net was $14.1 billion for Q1 2026 at Astrazeneca, down from $15.2 billion in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $15.2 billion in Q4 2025 to a low of $7.2 billion in Q4 2022.
• Historically, Receivables - Net has averaged $11.6 billion across 5 years, with a median of $11.3 billion in 2023.
• Biggest YoY gain for Receivables - Net was 74.97% in 2022; the steepest drop was 25.22% in 2022.
• A 5-year view of Receivables - Net shows it stood at $7.2 billion in 2022, then surged by 68.14% to $12.1 billion in 2023, then grew by 6.98% to $13.0 billion in 2024, then gained by 17.0% to $15.2 billion in 2025, then slipped by 7.06% to $14.1 billion in 2026.
• The last three Receivables - Net figures came in at $14.1 billion (Q1 2026), $15.2 billion (Q4 2025), and $14.3 billion (Q3 2025), per Business Quant data.